Pyrotinib
Phase 3Small molecule
Pyrotinib is used to treat certain types of breast cancer, particularly those that have specific genetic mutations (HER2 mutations) that make cancer cells grow faster.[1] Pyrotinib is currently being investigated across 12 indications[3], with its most advanced program in Phase 3.[1]
Pyrotinib is one of 229 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
12
Indications
96
Total Trials
45
Active Trials
228
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Pyrotinib
HHengrui Therapeutics, Inc.
Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer68 trials
Show 65 more trials
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
Not yet recruiting·—·Phase 2·NCT07132242·84 enrolled
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07340398·200 enrolled
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Active, not recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04398914·216 enrolled
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07065435·74 enrolled
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04872985·140 enrolled
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University··NCT04899128·100 enrolled
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT06495541·500 enrolled
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
Not yet recruiting·—·Phase 2·NCT07019337·100 enrolled
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05823623·30 enrolled
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05834764·188 enrolled
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06278870·312 enrolled
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04681911·71 enrolled
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 2·NCT05429294·209 enrolled
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04717531·60 enrolled
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT05429684·120 enrolled
An Open-Label, Single-Center, Exploratory Phase Ib/II Clinical Study of Entinostat Combined With Pyrotinib Plus Endocrine Therapy in Patients With Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Preclinical·NCT07708194·94 enrolled
Pyrotinib5 trials
Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04063462·60 enrolled
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Completed·—··NCT04756921·30 enrolled
Non-Small Cell Lung Cancer3 trials
Colorectal Cancer2 trials
HER2 + Breast Cancer2 trials
16 more indications
Salivary Gland Cancer1 trial
Maintenance Therapy1 trial
Unresectable1 trial
Adenocarcinoma1 trial
HER2 Positive1 trial
Medication Adherence1 trial
Metastasis1 trial
Efficacy and Safety1 trial
First-line Treatment1 trial
Locally Advanced or Metastatic NSCLC1 trial
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Not yet recruiting·—·Phase 2·NCT06185400·108 enrolled
HER2-Positive Solid Tumor1 trial
Non-squamous NSCLC1 trial
Breast Cancer Early Stage Breast Cancer (Stage 1-3)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pyrotinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Epidermal Growth Factor Receptor Erbb1 Inhibitor; Receptor Protein-Tyrosine Kinase Erbb-2 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHengrui Therapeutics, Inc.